News & Updates

The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).

Many paediatric sexual assault victims do not receive hepatitis B virus (HBV) postexposure vaccination and have low compliance to HIV postexposure prophylaxis (PEP), reveals a study in Singapore.

Twice-yearly subcutaneous (SC) lenacapavir demonstrates high efficacy, favourable safety, and consistent pharmacokinetics (PK) as pre-exposure prophylaxis (PrEP) for HIV-negative youth (aged 16–25 years) in an analysis of the phase III PURPOSE 1 (P1) and PURPOSE 2 (P2) trials.

The use of antibiotic therapy for 30 days following robot-assisted radical cystectomy (RARC) results in reduced 90-day urinary tract infections (UTIs), infectious complications, UTI-related readmissions, and costs without an increase in adverse events (AEs), a study has shown.